Absorica isotretinoin

Brand name

Absorica

Generic name

isotretinoin

Side effects of Absorica

  • mental health problems (such as depression, psychosis, or thoughts of suicide)
  • fatigue
  • skin reactions such as infections or rash
  • dry skin
  • bone or joint pain
  • eye inflammation (dry eyes, burning, redness, itching)
  • difficulty moving
  • dry nose that can lead to nosebleeds
  • inflammation of the lips (including chapping, scaling, redness, pain, burning)
  • abdominal pain

Warning for Absorica

WARNING

CAUSES BIRTH DEFECTS

Pregnancy Category X ABSORICA must not be used by female patients who are or may become pregnant. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking ABSORICA in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. Birth defects which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion and premature births have been reported. Documented external abnormalities include: skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia; facial dysmorphia; cleft palate). Documented internal abnormalities include: CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases death has occurred with certain abnormalities previously noted. If pregnancy does occur during the treatment of a female patient who is taking ABSORICA, ABSORICA must be discontinued immediately and she should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling. Special Prescribing Requirements Because of the risk of teratogenicity and to minimize fetal exposure, ABSORICA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called iPLEDGEâ„¢. Under the ABSORICA REMS, prescribers, patients, pharmacies, and distributors must enroll and be registered in the program.

show more